Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis

Bibliography

• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445(7130):866-73
   PubMed Web of Science ®Google Scholar
• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14-17
   PubMed Web of Science ®Google Scholar
• Ceponis A, Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol 2010;28(5 Suppl 61):S132-7
   PubMed Web of Science ®Google Scholar
• Huynh D, Kavanaugh A. Psoriatic arthritis: current therapy and future approaches. Rheumatology (Oxford) 2015;54(1):20-8
   PubMed Web of Science ®Google Scholar
• Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis 2011;70(Suppl 1):i77-84
   PubMed Web of Science ®Google Scholar
• Vander Cruyssen B, Hoffman IE, Zmierczak H, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005;64(8):1145-9
   PubMed Web of Science ®Google Scholar
• Colebatch AN, Marks JL, Van der heijde DM, Edwards CJ. Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a cochrane systematic review. J Rheumatol 2012;90:62-73
   Google Scholar
• Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology 2010;49(7):1367-73
   PubMed Web of Science ®Google Scholar
• Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008;67(6):855-9
   PubMed Web of Science ®Google Scholar
• Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64(6):859-64
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71(1):4-12
   PubMed Web of Science ®Google Scholar
• Coates LC, Ritchlin CT, Kavanaugh AF. GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting. J Rheumatol 2014;41(6):1237-9
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60(4):643-59
   PubMed Web of Science ®Google Scholar
• Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010;69(1):43-7
   PubMed Web of Science ®Google Scholar
• Saurat JH, Guerin A, Yu AP, et al. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology 2010;220(2):128-37
   PubMed Web of Science ®Google Scholar
• Brenner M, Molin S, Ruebsam K, et al. Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment. Br J Dermatol 2009;161(4):964-6
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50(7):2264-72
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52(10):3279-89
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60(4):976-86
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64(8):1150-7
   PubMed Web of Science ®Google Scholar
• Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014;73(1):48-55
   PubMed Web of Science ®Google Scholar
• Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010;11:180-210
   PubMedGoogle Scholar
• Schett G, Sloan VS, Stevens RM, Schafer P. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskelet Dis 2010;2(5):271-8
   PubMedGoogle Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012;83(12):1583-90
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal 2014;26(9):2016-29
   PubMed Web of Science ®Google Scholar
• Apremilast. 2015. Available from: http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=4805
   Google Scholar
• Tasken K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 2004;84(1):137-67
   PubMed Web of Science ®Google Scholar
• Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007;76(1):481-511
   PubMedGoogle Scholar
• Salvarani C, Macchioni P, Olivieri I, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001;28(10):2274-82
   PubMed Web of Science ®Google Scholar
• Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;10(22):1503-19
   PubMed Web of Science ®Google Scholar
• Heystek HC, Thierry AC, Soulard P, Moulon C. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int Immunol 2003;15(7):827-35
   PubMedGoogle Scholar
• Tenor H, Hedbom E, Hauselmann HJ, et al. Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4. Br J Pharmacol 2002;135(3):609-18
   PubMedGoogle Scholar
• Conti M, Richter W, Mehats C, et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 2003;278(8):5493-6
   PubMed Web of Science ®Google Scholar
• Shepherd MC, Baillie GS, Stirling DI, Houslay MD. Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. Br J Pharmacol 2004;142(2):339-51
   PubMedGoogle Scholar
• Bjorgo E, Tasken K. Novel mechanism of signaling by CD28. Immunol Lett 2010;129(1):1-6
   PubMedGoogle Scholar
• Jimenez JL, Punzon C, Navarro J, et al. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther 2001;299(2):753-9
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159(4):842-55
   PubMed Web of Science ®Google Scholar
• Schudt C, Winder S, Forderkunz S, et al. Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai. Naunyn Schmiedebergs Arch Pharmacol 1991;344(6):682-90
   PubMed Web of Science ®Google Scholar
• Jones NA, Boswell-Smith V, Lever R, Page CP. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 2005;18(2):93-101
   PubMed Web of Science ®Google Scholar
• Cockerill PN, Shannon MF, Bert AG, et al. The granulocyte-macrophage colony-stimulating factor/interleukin 3 locus is regulated by an inducible cyclosporin A-sensitive enhancer. Proc Natl Acad Sci USA 1993;90(6):2466-70
   PubMedGoogle Scholar
• Liu J, Chen M, Wang X. Calcitonin gene-related peptide inhibits lipopolysaccharide-induced interleukin-12 release from mouse peritoneal macrophages, mediated by the cAMP pathway. Immunology 2000;101(1):61-7
   PubMedGoogle Scholar
• Alves AC, Pires AL, Cruz HN, et al. Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro. Eur J Pharmacol 1996;312(1):89-96
   PubMedGoogle Scholar
• Man HW, Schafer P, Wong LM, et al. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihy dro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem 2009;52(6):1522-4
   PubMed Web of Science ®Google Scholar
• Parry GC, Mackman N. Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. J Immunol 1997;159(11):5450-6
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Adcock IM. Transcription factors and asthma. Eur Respir J 1998;12(1):221-34
   PubMedGoogle Scholar
• Ollivier V, Parry GC, Cobb RR, et al. Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem 1996;271(34):20828-35
   PubMed Web of Science ®Google Scholar
• Seldon PM, Barnes PJ, Meja K, Giembycz MA. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol 1995;48(4):747-57
   PubMedGoogle Scholar
• Kwak HJ, Song JS, Heo JY, et al. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther 2005;315(3):1188-95
   PubMed Web of Science ®Google Scholar
• Borska L, Fiala Z, Krejsek J, et al. Immunologic changes in TNF-alpha, sE-selectin, sP-selectin, sICAM-1, and IL-8 in pediatric patients treated for psoriasis with the Goeckerman regimen. Pediatr Dermatol 2007;24(6):607-12
   PubMedGoogle Scholar
• Schafer P, Chen P, Fang L, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: pharmacodynamic results of a phase 3, randomized, controlled trial [abstract]. 78th Annual scientific meeting of the American College of Rheumatology and the 48th Annual meeting of the Association of Rheumatology Health Professionals. 2014
   Google Scholar
• Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008;24(5):1529-38
   PubMed Web of Science ®Google Scholar
• Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009;131(2):308-16
   PubMed Web of Science ®Google Scholar
• Claveau D, Chen SL, O’Keefe S, et al. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan- 2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 2004;310(2):752-60
   PubMedGoogle Scholar
• Gilhar A, Ullmann Y, Kerner H, et al. Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors. J Invest Dermatol 2002;119(2):384-91
   PubMed Web of Science ®Google Scholar
• Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012;380(9843):738-46
   PubMed Web of Science ®Google Scholar
• Strand V, Fiorentino D, Hu C, et al. Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Health Qual Life Outcomes 2013;11:82
   PubMed Web of Science ®Google Scholar
• Papp KA, Kaufmann R, Thaci D, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol 2013;27(3):e376-83
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Menter A, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol 2013;12(8):888-97
   PubMed Web of Science ®Google Scholar
• McCann FE, Palfreeman AC, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther 2010;12(3):R107
   PubMed Web of Science ®Google Scholar
• Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012;64(10):3156-67
   PubMed Web of Science ®Google Scholar
• Cutolo M, Poder A, Myerson G, et al. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2). Arthritis.Rheum 2013;65(10 Suppl):S347
   Google Scholar
• Birbara C, Blanco FJ, Crowley JJ, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis including current skin involvement: Results of a Phase 3, randomized, controlled trial (PALACE 3). 14th Annual European League Against Rheumatism (EULAR); Madrid, Spain; 2013
   Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014;73(6):1020-6
   PubMed Web of Science ®Google Scholar
• Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast in the Treatment of DMARD-Naive Psoriatic Arthritis Patients: Results of a Phase 3 Randomized, Controlled Trial (PALACE 4) [abstract]. 77th Annual Scientific Meeting of the American College of Rheumatology (ACR) and the 48th Annual Meeting of the Association of Rheumatology Health Professionals (ARHP); San Diego, CA, USA; 2013
   Google Scholar
• Gladman DD, Mease PJ, Kavanaugh A, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: pooled results from three phase 3 randomized, controlled trials. Arthritis Rheum 2013;65(10 Suppl):S347
   Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis. J Rheumatol 2015;42(3):479-88
   PubMed Web of Science ®Google Scholar
• Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for the treatment of Behçet’s syndrome: a phase II randomized, placebo-controlled, double-blind study. Arthritis Rheum 2013;65(10 Suppl):S322
   Google Scholar
• Gordon JN, Prothero JD, Thornton CA, et al. CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-alpha and MMP-3 production in patients with inflammatory bowel disease. J Crohns Colitis 2009;3(3):175-82
   PubMedGoogle Scholar
• Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005;365(9454):167-75
   PubMed Web of Science ®Google Scholar
• Martina SD, Ismail MS, Vesta KS. Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease. Ann Pharmacother 2006;40(10):1822-8
   PubMedGoogle Scholar
• Schreiber S, Keshavarzian A, Isaacs KL, et al. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology 2007;132(1):76-86
   PubMed Web of Science ®Google Scholar
• Papp K, Zeldis JB, Rohane P, Thaci D. A phase 2 study demonstrating the efficacy and safety of the oral therapy CC-1004 in subjects with moderate to severe psoriasis [abstract P2614]. J Am Acad Dermatol 2008;58:AB3
   Google Scholar
• Robichaud A, Stamatiou PB, Jin SL, et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002;110(7):1045-52
   PubMed Web of Science ®Google Scholar
• Marvin MG. Pharmaceutical approval update. P T 2014;39(6):415
   PubMedGoogle Scholar